222 related articles for article (PubMed ID: 23287700)
1. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.
Kangas BD; Delatte MS; Vemuri VK; Thakur GA; Nikas SP; Subramanian KV; Shukla VG; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Mar; 344(3):561-7. PubMed ID: 23287700
[TBL] [Abstract][Full Text] [Related]
2. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; LeMay BJ; Vemuri VK; Vadivel SK; Zvonok A; Makriyannis A
Psychopharmacology (Berl); 2011 Aug; 216(3):355-65. PubMed ID: 21369753
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
4. Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.
Paronis CA; Chopda GR; Vemuri K; Zakarian AS; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2018 Mar; 364(3):485-493. PubMed ID: 29311110
[TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.
Järbe TU; Li C; Vadivel SK; Makriyannis A
Psychopharmacology (Berl); 2008 Jul; 198(4):467-78. PubMed ID: 18264696
[TBL] [Abstract][Full Text] [Related]
6. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.
Desai RI; Thakur GA; Vemuri VK; Bajaj S; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Feb; 344(2):319-28. PubMed ID: 23197773
[TBL] [Abstract][Full Text] [Related]
7. Effects of the cannabinoid CB
AlKhelb D; Kirunda A; Ho TC; Makriyannis A; Desai RI
Drug Alcohol Depend; 2022 Nov; 240():109646. PubMed ID: 36191533
[TBL] [Abstract][Full Text] [Related]
8. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2009 Apr; 203(2):219-28. PubMed ID: 18592221
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.
Järbe TU; LeMay BJ; Olszewska T; Vemuri VK; Wood JT; Makriyannis A
Pharmacol Biochem Behav; 2008 Nov; 91(1):84-90. PubMed ID: 18640150
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.
Kangas BD; Zakarian AS; Vemuri K; Alapafuja SO; Jiang S; Nikas SP; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2020 Jan; 372(1):119-127. PubMed ID: 31641018
[TBL] [Abstract][Full Text] [Related]
11. Diuretic effects of cannabinoids.
Paronis CA; Thakur GA; Bajaj S; Nikas SP; Vemuri VK; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Jan; 344(1):8-14. PubMed ID: 23019138
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabinoid agonists and antagonists in male rats discriminating the synthetic cannabinoid AM2201.
AlKhelb D; Burke EL; Zvonok A; Iliopoulos-Tsoutsouvas C; Georgiadis MO; Jiang S; Ho TC; Nikas SP; Makriyannis A; Desai RI
Eur J Pharmacol; 2023 Dec; 960():176168. PubMed ID: 38059442
[TBL] [Abstract][Full Text] [Related]
14. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
[TBL] [Abstract][Full Text] [Related]
16. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.
Hruba L; McMahon LR
Eur J Pharmacol; 2014 Mar; 727():35-42. PubMed ID: 24486701
[TBL] [Abstract][Full Text] [Related]
17. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.
Järbe TU; Li C; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2009 Apr; 203(2):229-39. PubMed ID: 18521574
[TBL] [Abstract][Full Text] [Related]
19. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
20. JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.
Rodriguez JS; McMahon LR
Eur J Pharmacol; 2014 Oct; 740():151-9. PubMed ID: 24972243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
